Stocktoria
NORTHWEST BIOTHERAPEUTICS INC NWBO
OTC · OOTC · stock · Pharmaceutical Preparations · website · IPO 2001-12-14
NORTHWEST BIOTHERAPEUTICS INC (NWBO) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $1.4M at a -4365.9% net margin.
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Market cap$304M
Net margin-4365.9%
Revenue trend · last 10y · up
How it ranks in Manufacturing · percentile among 1829 companies
Piotroski Fstronger than 44%
Net marginstronger than 5%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
| VTGN | Vistagen Therapeutics, Inc. | 2/9 | — | — | — |
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| DARE | Dare Bioscience, Inc. | 3/9 | — | — | — |
FAQ
Is NWBO financially healthy?
NORTHWEST BIOTHERAPEUTICS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does NWBO pay a dividend?
No, NORTHWEST BIOTHERAPEUTICS INC does not currently pay a dividend.
How profitable is NWBO?
In FY2025, NORTHWEST BIOTHERAPEUTICS INC had a net margin of -4365.9%.
Source: SEC EDGAR filings · CIK 0001072379 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.